CA3048036A1 — Crystalline form of ribociclib succinate
Assigned to Apotex Inc · Expires 2020-01-02 · 6y expired
What this patent protects
The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, comprising Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the tr…
USPTO Abstract
The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, comprising Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.